Buy Tesamorelin 2mg
FDA-approved GHRH analog for visceral fat reduction and GH restoration
Trusted Tesamorelin 2mg — Tesamorelin (Egrifta) is an FDA-approved GHRH analog specifically indicated for HIV-associated lipodystrophy, demonstrating 15–20% reduction in visceral fat in clinical trials.
- FDA-approved for visceral fat reduction (Egrifta)
- 15–20% reduction in visceral adipose tissue in clinical trials
- Restores GH and IGF-1 via hypothalamic GHRH receptor activation
- Specifically targets visceral fat — the most dangerous fat depot
- Preserves GH pulsatility and feedback regulation
COA verified · US domestic shipping
Tesamorelin: The FDA-Approved GHRH Analog With Clinical Evidence for 15–20% Visceral Fat Reduction
FDA Approved for Fat Reduction
Tesamorelin (Egrifta) is FDA-approved specifically for visceral fat reduction — the only GHRH analog with regulatory approval for a body composition indication.
15–20% Visceral Fat Loss
Randomized controlled trial data shows 15–20% reduction in VAT over 26 weeks — clinical-grade evidence for GH-mediated visceral fat reduction.
Visceral Fat Specificity
GH-mediated lipolysis disproportionately targets visceral adipose tissue — the intra-abdominal fat depot most strongly linked to cardiovascular disease and metabolic syndrome.
Pituitary Pathway Preservation
Like all GHRH analogs, tesamorelin works through the pituitary to restore natural GH secretion — preserving feedback regulation versus the risks of direct GH replacement.
The Science Behind Tesamorelin 2mg
▸FDA-Approved for Visceral Fat Reduction
Tesamorelin (trade name Egrifta) is a synthetic GHRH analog that received FDA approval in 2010 for the treatment of HIV-associated lipodystrophy — a condition of excess visceral fat accumulation caused by antiretroviral therapy. It is unique among GHRH analogs in having specific FDA approval for a fat-reducing indication, with randomized controlled trial data demonstrating 15–20% reductions in visceral adipose tissue (VAT) after 26 weeks.
▸Mechanism: GHRH-Mediated GH and IGF-1 Restoration
Tesamorelin activates pituitary GHRH receptors to restore GH secretion, which is often suppressed in lipodystrophy states. The resulting increase in GH and downstream IGF-1 drives lipolysis in visceral adipose tissue specifically — the fat depot most strongly regulated by GH. This GH-mediated visceral fat reduction is distinct from general weight loss and specifically targets the metabolically dangerous intra-abdominal fat depot.
▸Beyond HIV: Body Composition Applications
The mechanism of GH-restored visceral fat reduction is relevant beyond HIV lipodystrophy — any individual with suppressed GH secretion (due to aging, obesity, stress, or other factors) and excess visceral fat may benefit from tesamorelin's GHRH-mediated GH restoration. Research is ongoing in non-HIV lipodystrophy, obesity, and cognitive function in aging.
Complete Tesamorelin 2mg Benefits
- FDA-approved for visceral fat reduction (Egrifta)
- 15–20% reduction in visceral adipose tissue in clinical trials
- Restores GH and IGF-1 via hypothalamic GHRH receptor activation
- Specifically targets visceral fat — the most dangerous fat depot
- Preserves GH pulsatility and feedback regulation
- Improves lipid profile and metabolic markers alongside fat reduction
- Research applications in aging and age-related visceral adiposity
Tesamorelin 2mg Dosing Protocol
Reconstitution: Add 0.5mL sterile water for injection per 2mg vial.
Dosing:
• FDA-indicated dose: 2mg subcutaneous daily
• Research protocol: 1–2mg subcutaneous daily
• Cycle: 26 weeks per FDA trial design; ongoing use possible
Timing: Morning injection; clinical protocol uses daily dosing
All information on this site is for educational purposes only. Always consult with a qualified healthcare provider before use. COA documentation is available for all products.
Tesamorelin 2mg
COA verified · Third-party tested · US domestic shipping
Buy Now View Stack ProtocolsBody composition peptides optimize the GH/IGF-1 axis and metabolic signaling for simultaneous fat loss and muscle gain.
All Body Composition PeptidesStacks Best With
Stack Tesamorelin 2mg With
Weight LossAOD9604 5mg
Larger supply HGH lipolytic fragment for extended fat loss protocols
Buy AOD9604 5mg — AOD9604 5mg — extended supply of the hGH lipolytic fragment for longer fat loss cycles without mid-protocol reconstitution.
Body CompositionIpamorelin 10mg
Selective GHRP for clean GH release without cortisol or prolactin elevation
Buy Ipamorelin 10mg — Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates pulsatile GH release with minimal cortisol, prolactin, or acetylcholine side effects.
Body CompositionSermorelin 5mg
FDA-approved GHRH(1-29) analog for GH optimization and anti-aging
Sermorelin 5mg For Sale — Sermorelin is the first 29 amino acids of GHRH, formerly FDA-approved for pediatric GH deficiency — stimulates pulsatile GH release for anti-aging and body composition without exogenous HGH risks.